Misplaced Pages

This is an old revision of this page, as edited by Beetstra (talk | contribs) at 09:30, 31 October 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank', 'UNII', 'ChEMBL', 'CAS_number').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Peginterferon alfa-2a" – news · newspapers · books · scholar · JSTOR (November 2008) (Learn how and when to remove this message)

Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.

Uses

This drug is approved around the world for the treatment of chronic hepatitis C (including patients with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B.

Peginterferon alfa-2a is a long acting interferon. Interferons are proteins released in the body in response to viral infections. Interferons are important for fighting viruses in the body, for regulating reproduction of cells, and for regulating the immune system.

Host genetic factors influencing treatment response

For genotype 1 hepatitis C treated with Pegylated interferon-alpha-2a or Pegylated interferon-alpha-2b (brand names Pegasys or PEG-Intron) combined with ribavirin, it has been shown genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in response to the treatment. This finding, originally reported in Nature , showed genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others. Later report from Nature demonstrated the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus.

See also

• Interferon
• PEGylation

References

1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
2. Ge D, Fellay J, Thompson AJ; et al. (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. doi:10.1038/nature08309. PMID 19684573. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
3. Thomas DL, Thio CL, Martin MP; et al. (2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature. 461 (7265): 798–801. doi:10.1038/nature08463. PMID 19759533. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)

External links

• Interferon and hepatitis c at pegasys.com
• PMPRB at pmprb-cepmb.gc.ca
• Chemical structure at hepalife.com
• Pegasys at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Antivirals
• Immunostimulants
• Antiinfective agent stubs
• Antineoplastic and immunomodulating drug stubs